Wells Fargo Begins Covering uniQure (QURE) Stock. “Shares to Hit $47.0”

May 16, 2018 - By Marie Mckinney

uniQure N.V. (NASDAQ:QURE) Logo

Why Has Wells Fargo Given uniQure (QURE) a $47.0 Price Target

Analysts at Wells Fargo initiated coverage on shares of uniQure (QURE) in analysts report published on Wednesday morning. The financial company set “Outperform” rating on the $1.20B market cap company.

The stock increased 2.82% or $0.89 during the last trading session, reaching $32.4. About 336,178 shares traded. uniQure N.V. (QURE) has risen 293.97% since May 17, 2017 and is uptrending. It has outperformed by 282.42% the S&P500.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on August, 14. They expect $-0.68 earnings per share, up 18.07 % or $0.15 from last year’s $-0.83 per share. After $-0.59 actual earnings per share reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 15.25 % negative EPS growth.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.20 billion. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 16, 2018, also Streetinsider.com with their article: “Wells Fargo Starts uniQure BV (QURE) at Outperform” published on May 16, 2018, Nasdaq.com published: “uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters’ Option To Purchase Additional …” on May 07, 2018. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on May 11, 2018 as well as Seekingalpha.com‘s news article titled: “Genomic Medicine: Catch The Gene Therapy Wave” with publication date: May 14, 2018.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.